November 2019—Memorial Sloan Kettering Cancer Center announced that the New York State Department of Health has issued an approval for its Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS) molecular assay. MSK-ACCESS was developed in the Marie-Josée and Henry R. Kravis Center for Molecular Oncology and has been clinically validated and implemented by members of MSK’s molecular diagnostics service.
The MSK-ACCESS assay is a comprehensive liquid biopsy test that offers noninvasive cancer genomic profiling and disease monitoring. It involves the deep sequencing of 129 key cancer-associated genes selected from MSK’s solid tumor genomic-profiling assay, MSK-IMPACT. MSK-ACCESS is designed to detect genetic alterations in cell-free DNA specimens.